Nautilus collaboration bears first fruit
milestone in a collaboration with Aventis Pasteur, designed to
improve the productivity of the latter's vaccine manufacturing
process.
Nautilus has developed a number of cell clones in the collaboration that have been shown to provide improvements in virus yield, and some of these clones are now being developed further at Aventis Pasteur.
Nautilus has received an undisclosed milestone payment from Aventis Pasteur under the terms of the agreement signed between the two companies in September 2002. The collaboration, Nautilus' first, is focused on developing improved production vehicles for three vaccine products.
Nautilus' has developed a high throughput system, called Platform Biomics, that uses viral vectors or plasmids to create a range of genetic modifications in a cell line. In addition to creating modified cell lines, the technology can be used to evolve new variants of a target protein to improve its profile, for example by reducing toxicity whilst retaining its pharmacological activity.
